FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaUğur Şahin, S. Al-Batran, Ahsan M. Arozullah et al.|Annals of Oncology|2021Cited by 357